Caplin Point Laboratories

₹2,382As of Sun 8 Nov 2026, 12:00 UTC
NSE:CAPLIPOINTHealthcare
Country India
PE (Fwd) 23.61
TSR 10Y CAGR 20.21%
Div yield 0.34%
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.46
PE TTM 28.33
TSR TTM 17.62%
Mkt cap ₹177.6B
ROIC —
SE Grade™
Value
Quality
Moat
1Y Price
Reference
₹2,648
11.14%
(61.64%)
Price above Reference Value
FY23
FY24
FY25
FY26
Earnings per share₹
49.18
59.90
70.25
84.11
25.27%
21.80%
17.28%
19.73%
Revenue₹B
14.68
16.96
19.40
21.90
15.53%
15.51%
14.35%
12.89%
TTM
FYE 31 Mar INR
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
FY2027E
Trend
5Y
10Y
Peers
21.90
Revenue₹B
—
—
—
—
—
12.71
14.68
16.96
19.40
21.90
24.05
14.57%
14.57%
23
12.89
Revenue growth%
—
—
—
—
—
—
15.53
15.51
14.35
12.89
9.82
14.93
—
73
58.83
Gross margin%
—
—
—
—
—
54.96
53.74
55.42
58.67
58.83
58.80
55.42
55.42
48
31.72
Operating margin%
—
—
—
—
—
27.51
27.13
29.53
30.27
31.72
31.71
29.53
29.53
93
29.29
Net margin%
—
—
—
—
—
23.59
25.63
26.95
27.65
29.29
29.35
26.95
26.95
97
28.33
P/E ratio (avg)x
—
—
—
—
—
19.47
14.48
18.58
27.22
23.23
25.74
19.47
19.47
42
26.15
EV/EBITx
—
—
—
—
—
16.69
13.67
16.95
24.87
21.45
23.82
16.95
16.95
24
—
FCF yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
33
—
FCF margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
60
—
FCF / Net incomex
—
—
—
—
—
—
—
—
—
—
—
—
—
16
—
ROIC%
—
—
—
—
—
—
—
—
—
—
—
—
—
83
—
Return on equity%
—
—
—
—
—
—
—
—
—
—
—
—
—
81
—
Return on assets%
—
—
—
—
—
—
—
—
—
—
—
—
—
93
84.11
EPS₹
—
—
—
—
—
39.26
49.18
59.90
70.25
84.11
92.57
20.98%
20.98%
—
19.73
EPS growth%
—
—
—
—
—
—
25.27
21.80
17.27
19.73
10.06
20.77
—
64
—
Bookvalue per sh₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
FCF per share₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
8.00
Dividend per sh₹
—
—
—
—
—
4.00
4.50
5.00
6.00
8.00
8.58
18.92%
18.92%
—
0.34
Div yield (avg)%
—
—
—
—
—
0.52
0.63
0.45
0.31
0.41
0.36
0.45
0.45
10
9.51
Payout ratio%
—
—
—
—
—
10.19
9.15
8.35
8.54
9.51
9.27
9.15
9.15
12
76.24
Shares (diluted)M
—
—
—
—
—
76.37
76.51
76.31
76.35
76.24
◌76.24
(0.04%)
(0.04%)
69
0.14
Buyback yield%
—
—
—
—
—
—
(0.18)
0.26
(0.05)
0.14
◌—
0.05
—
69
—
D/E ratiox
—
—
—
—
—
—
—
—
—
—
—
—
—
100
181.6
Enterprise value₹B
—
—
—
—
—
58.37
54.47
84.93
146.0
149.0
181.6
26.40%
26.40%
30
—
LT debt₹M
—
—
—
—
—
—
—
—
—
—
—
—
—
0
Peers (US$1.922B)
Cap (US$)
PE
1.926B
13.11x
Capital
TTM
5Y
10Y
Leveragex
—
—
—
EBIT/Intx
798.4
642.2
642.2
Own earn%
—
—
—
Sh yield%
0.48
0.50
0.50
Owners
Insiders/Inst%
67.49
5.93
Short interest%
—
SBC / revenue%
(0.06)
Record
10Y
Profitable years
5/5
Revenue growth years
4/4
EPS growth years
4/4
Dividend streakyrs
11
Op margin range%
27–32
$1 testx
—
Incr. ROIC%
—

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion.

Growth vs revenue
Latest
Trend
4Y CAGR
Rel growth
Revenue
₹21.90B
14.57%
1.00×
Cost of revenue
₹9.014B
12.02%
0.91×
Operating expenses
₹5.936B
14.20%
0.99×
Revenue by region
No breakdown available
Reinvestment returns
n/m
Trend
Reinvestment rate
n/m
-
Return on capital
n/m
-
Spread over hurdle
n/m
-